ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Six-year Follow-Up of Nonpharmacological and Nonsurgical Obesity Treatments.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The prevalence of obesity and its cardiometabolic consequences are increasing worldwide. Scalable and affordable methods to obtain and maintain weight loss and prevent comorbidities such as type 2 diabetes (T2D) are major goals for obesity care. We performed a long-term follow-up study based on self-report after attending different nonpharmacological weight loss treatments at a university center when modern obesity drugs were not yet available. Patients and Methods: A total of 1,130 subjects were invited. Response rate was 67% and treatment and follow-up times were 1.4±0.04 and 6.1±0.1 years (mean±SEM), respectively. The treatment groups were: Individual therapy (IT; n=156); Group-based behavioral therapy (GT; n=285); GT initiated by low-calorie diet (LCD-GT; n=136); and bariatric surgery (BS) at any time after attending the center (n=152). A total of 145 subjects had T2D at baseline. Results: 57.8% (95% CI 54.1-61.5) and 36.4% (32.9-40.0) of subjects achieved >5% and >10% body weight loss, respectively. At follow-up, this translated into 96.7 (92.5-98.9) and 92.1% (86.6-95.9) of subjects who went on to BS achieving >5% and >10% weight loss compared to 48.1 (43.9-52.4) and 30.9% (27.1-34.9) in the non-surgery (NS) subgroups. The LCD-GT subgroup experienced the largest weight loss, but also the greatest weight regain among the NS subgroups; 56.7 (47.9-65.2) and 41.8% (33.3-50.6) maintaining a >5% and >10% loss of weight at follow-up. Incident T2D was lower (2.6% [0.5-7.4] vs 9.2% [6.7-12.2], Conclusion: In real-world practice, bariatric surgery fulfils the promise of academic trials. However, nonsurgical and nonpharmacological treatments can also have a long-term impact on both weight loss and diabetes prevention and remission. This is important because modern obesity drugs and bariatric surgery are not available or affordable for most obese people.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.